-
H.C. Wainwright Downgrades HilleVax, Inc. (HLVX) to Neutral
-
Stifel Downgrades HilleVax, Inc. (HLVX) to Hold
-
Guggenheim Downgrades HilleVax, Inc. (HLVX) to Neutral
-
JPMorgan Downgrades HilleVax, Inc. (HLVX) to Overweight
-
HilleVax (HLVX) shares sink as HIL-214 results disappoint
-
HilleVax (HLVX) to Resume Trading at 8 a.m.
-
HilleVax (HLVX) Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
-
HilleVax (HLVX) Halted, News Pending

